Topic resource collection
Approved comparison material connected to this topic.
3 resourcesRead both sides
CJC-1295 with DAC (Drug Affinity Complex) extends the half-life of growth hormone-releasing hormone (GHRH) from 7 minutes to approximately 8 days, maintaining elevated plasma GH levels throughout the dosing interval. This produce…
CJC-1295 (with DAC) GHRH analog. Extends endogenous GH half-life from 7 minutes to 6–8 days, amplifies pulse amplitude Pituitary GHRH receptors 1–2mg weekly (subcutaneous) 4–6 weeks for visceral adipose reduction measurable via i…
Survodutide (GLP-1/Glucagon) Incretin receptor agonism + hepatic fat oxidation High. Glucagon receptors densely expressed in visceral adipocytes 15.7% body weight reduction, 18.2% visceral fat reduction (Phase 2, The Lancet) ~5 d…